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Abstract 
We introduce Phen-Gen, a method which combines patient’s disease symptoms and sequencing 
data with prior domain knowledge to identify the causative gene(s) for rare disorders. 
Simulations reveal that the causal variant is ranked first in 88% cases when it is coding; which is 
52% advantage over a genotype-only approach and outperforms existing methods by 13-58%. If 
disease etiology is unknown, the causal variant is assigned top-rank in 71% of simulations.  
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Introduction 
Rare disorder analysis has been facilitated by next generation sequencing. The diagnostic yield 
in large clinical studies remains moderate, varying between 16-50%1,2. The cause of two-thirds 
of new cases remains unknown3 and nearly half of OMIM-reported disorders have an unknown 
molecular basis4. Issues that may be limiting the success of a study include focus on coding 
exome with exclusion of potential regulatory variants5, and lack of systematic integration of 
prior knowledge of disease and gene(s) involved. More recently there has been a shift in 
paradigm to incorporate patient symptoms in the causative gene prediction; eXtasy6, PHIVE7 
and PHEVOR8 are recent examples. However each has its limitations and none of the existing 
symptom-driven methods extend across the entire genome.  
We introduce Phen-Gen, a method which combines the patient's sequencing data and 
symptoms with prior knowledge of human diseases and functional interplay of different genes, 
all within a systematic Bayesian framework (Supplementary Fig. 1). The method offers two 
alternate paths to disease-gene implication. Phen-Gen’s exome-centric approach predicts the 
damaging impact of coding mutations using nonsynonymous, splice site, and indel predictors 
within a unifying framework (Supplementary Figs. 2 and 3). This allows for a direct quantitative 
comparison between coding variants. Phen-Gen’s genome-wide approach utilizes evolutionary 
conservation, ENCODE predicted functionality, and proximity to coding sequence to estimate 
disease functionality of a locus (Supplementary Figs. 4 and 5). Both approaches take into 
account that healthy humans harbor hundreds of supposedly damaging mutations and certain 
genes are more prone to these so-called deleterious variants (Supplementary Fig. 6). 
To safeguard against overfitting, each component of our loosely coupled pipeline has been 
individually evaluated in cross-validation; before analyzing the complete method in totality. 
Phen-Gen assigns the causal gene first rank in 88% of simulations. It shows a 19-58% 
improvement in direct simulation comparison to previously published methods: eXtasy6, 
VAAST9, and PHEVOR8; and 13-16% improvement over results reported by PHIVE7 in a 
comparable simulation framework. For novel genes, unknown to our internal database, Phen-
Gen assigns first rank in 71% of simulations.  The efficacy of Phen-Gen is further established in 
real patient data from a recently published study2. The causal gene is ranked first in 8/11 
patients (and within top 5 in all). For ease of use and to address data privacy issues, Phen-Gen is 
available both as a web server and an open-source downloadable package (http://phen-
gen.com). 
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Results 
Prediction framework 
Phen-Gen combines disease symptoms and sequencing data to estimate the role of genes in 
rare disorders (Supplementary Fig. 1). The patient symptoms are semantically matched against a 
database of known human disorders using an in-house implementation of Phenomizer10. The 
potential role of novel but functionally similar genes is estimated using random walk with 
restart over a gene interaction network. This network was constructed by integrating seven data 
sources. The sequencing data is analyzed using an exome-centric approach and a genomic 
approach. The performances of Phen-Gen’s predictors for exome and genome have been 
quantified using enrichment of disease causal mutations, in conjunction with depletion of 
common polymorphisms. The phenotypic and genotypic predictions are combined and genes 
ranked based on the two corroboratory pieces of evidence.  
 
The performance of method is first evaluated at the variant level using Human Gene Mutation 
Database11 (HGMD 2011.4) reported disease variants across different subclasses 
(Supplementary Fig. 7).  In all three coding categories, 84% (or higher) mutations were predicted 
damaging with high probability (≥0.9). The genomic predictor was evaluated using HGMD 
reported disease causal regulatory variants; 80% were scored and 38% were assigned a 
damaging probability of 0.5 or higher. 
 
Simulated datasets  
We evaluated Phen-Gen with in silico patients. For a given disorder, a patient’s genetic data was 
created by adding a HGMD disease causal mutation into a healthy individual’s genome or 
exome. The patient’s phenotypic data was generated based on reported disease symptoms. 
Combining all dominant and recessive simulations, Phen-Gen assigns the disease causal variant 
first rank in 88% of the cases across different classes of coding variants (Table 1 and 
Supplementary Table 1). 
 
To ascertain the performance in implicating novel causal genes, we split the HGMD reported 
variants based on whether the disease-gene link is ‘known’ or ‘unknown’ to our local 
Phenomizer database.  When the gene is known, Phen-Gen assigns it the first rank in 92% cases 
for dominant and 96% cases for recessive diseases (Table 1). However even for unknown 
disorders, adding the disease symptoms improved the prediction and Phen-Gen is able to 
correctly identify the true gene in 43% of dominant and 92% of recessive disorders. To further 
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evaluate Phen-Gen’s role in novel disease-gene discovery, we masked the gene’s association 
with the disorder in the respective simulation. The results are comparable to the true unknown 
cases. Combining results from all unknown and masked simulations, Phen-Gen is able to assign 
first rank to disease causal variants in 71% cases (Supplementary Table 2). 
To evaluate any potential biases of using 1000 Genomes for both allele frequency estimation 
and generating in silico patients, the simulations were repeated using only Exome Sequencing 
Project (ESP)12 data in the common variant filtration step (Supplementary Table 3). We also 
evaluated the performance of our method in identifying the disease causal gene with a 
compound heterozygous disease inheritance pattern (Supplementary Table 4 and 
Supplementary Fig. 8). Moreover, to account for phenotypic heterogeneity, Phen-Gen was 
assessed by randomly sampled symptoms from 44 disorders for which the symptom list and 
their frequency of occurrence has been compiled10  (Supplementary  Table 5 and 
Supplementary Fig. 9).  
It is more challenging to narrow down the role of a particular noncoding variant in a rare 
disorder. Phen-Gen correctly identifies the genetic cause in 49% of cases with noncoding 
disease variants, with phenotypic information contributing substantially to the prediction 
(Supplementary Table 6). Moreover, the decoupled nature of the phenotypic and genotypic 
predictors within the unifying analysis framework bodes well to improving predictions as the 
regulatory role of different genomic sites is unraveled. 
Real datasets 
We also applied Phen-Gen to a study comprising of a hundred father-mother-child trio families 
with the child in each family suffering from intellectual disability symptoms1. Eleven families 
with variants implicated in recessive or X-mode inheritance were used in this evaluation. 81% 
(13/16) of the reported genes were ranked in the top 10 in our prediction (Table 3). In the 
original study all mutations reported in dbSNP or observed in the in-house dataset were 
removed from further evaluation. Phen-Gen, on the other hand, allows rare (below 1% MAF) 
variants from dbSNP. When the original study criterions were adopted, the predictions 
improved further.  8/11 patients were assigned an implicated gene as the top gene and all 
reported genes now ranked in the top 5 in the respective families (Supplementary Table 7).  
Comparison 
We evaluated Phen-Gen against VAAST9  and eXtasy6, both of which rank genes or variants 
based only on nonsynonymous mutations (Fig. 1). eXtasy under default setting ranks all 
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common and rare variants. In its manuscript it was also evaluated with rare variants (MAF<1%) 
separately. We show results under both scenarios. VAAST assigns top rank to an average of 14 
genes per simulation; whereas Phen-Gen and eXtasy assign a continuum of ranks with a lone 
gene assigned the top rank in each simulation. Phen-Gen assigns the causal gene top rank in 
82% cases for dominant disorders compared to 62% for VAAST and 24% for eXtasy. For recessive 
disorders, Phen-Gen assigns top rank in 97% cases compared to 78% for VAAST, and 30% for 
eXtasy. 
While Phen-Gen was in submission, PHEVOR8 was published by the authors of VAAST. PHEVOR 
combines multiple disease and functional ontologies to improve the performance of genomic 
predictors like VAAST. To evaluate its performance, 50 dominant and 50 recessive VAAST 
simulations were randomly chosen and the genes reprioritized using PHEVOR.  Phen-Gen 
identifies the causal gene in 90% of dominant and 88% of recessive simulations, while 
VAAST+PHEVOR assign the top rank in 66% and 68%, respectively (Fig. 1). In conclusion, Phen-
Gen outperforms VAAST, eXtasy, and VAAST+PHEVOR by 19-58%. 
PHIVE7 is another recently published method that integrates phenotypic information. It scores 
all exonic variants and matches human disease symptoms against a knockout mouse phenotype 
database using semantic similarity. In its publication, it was evaluated in a similar simulation 
framework albeit with a different disease set of HGMD variants. The authors report its ability to 
assign the disease causal gene first rank in 66% of cases for dominant and 83% of cases in 
recessive disorders. In comparison to PHIVE, Phen-Gen shows 16 and 13 percentage points’ 
advantage in identifying the true causal gene for dominant and recessive disorders respectively.  
The impact of regulatory variants in congenital disorders is well established13. FunSeq14 was 
recently published to predict the regulatory role of noncoding mutations. FunSeq’s results using 
HGMD regulatory variants indicate a strong enrichment of damaging mutations, but only 18% of 
the damaging regulatory variants fall within its first filtration criteria. In contrast, Phen-Gen 
assigns damaging probabilities to 80% of these variants (Supplementary Fig. 7).  
Phen-Gen highlights the advantage of integrating patient symptom information in 
understanding disease mechanism and works on both coding and noncoding variation. 
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Figure legend 
Figure 1  
Comparison with VAAST, eXtasy, and VAAST+PHEVOR 
The comparison of Phen-Gen, VAAST, eXtasy and VAAST+PHEVOR in simulations using OMIM 
disease symptoms and HGMD nonsynonymous mutations is shown. In each panel, the ability of 
the methods to narrow down the true gene search within 1, 5 and 10 genes is depicted. (a) The 
two panels reflect comparison with VAAST and eXtasy. For Phen-Gen the bar is split into the 
predictive power based on genotypic prediction and the added advantage gained from disease 
symptoms. VAAST only uses the genotype data and assign multiple genes the same rank at the 
top of the order. For a fair comparison, the true gene was assigned the worst, average and best 
VAAST rank among similarly ranked peers. For example, if VAAST assigns the true gene along 
with 4 other genes the same top rank, then the causal gene will be ranked as 1, 3 and 5 for best, 
average and worst respectively. The three components of the VAAST bar reflect the 
performance across the three scenarios. eXtasy ranks all rare and common variants. The two 
components of eXtasy bar reflect its performance under the default settings and the added 
advantage of discarding common variants (MAF>1%) from its input. (b) 50 dominant and 50 
recessive simulations were randomly chosen for comparison with PHEVOR. For VAAST only the 
best rank (among similarly ranked genes) is depicted. PHEVOR+VAAST bars highlight the added 
advantage of analyzing VAAST output in light of the phenotypic information by PHEVOR. 
9 
 
 
10 
 
Table 1 Performance in simulated patients for coding predictor 
Phen-Gen’s performance is evaluated with OMIM-listed disease symptoms and HGMD- reported 
variants for coding predictor. Across all simulations Phen-Gen assigns the causal variant top rank 
in 88% of cases. The results are categorized based on the class of the true causal variant and the 
table entries reflect the percentage of simulations in each category with the indicated result. 
The top three rows in each sub-table represent the performance of the complete method 
(genotype and phenotype), the genotype-only approach, and the phenotype-only approach 
respectively. The performance of Phen-Gen when the causal gene is previously known and 
unknown is depicted as well.   
  Dominant Recessive 
  
Top 
gene (%) 
Top 5 genes 
(%) 
Top 10 genes 
(%) 
Top gene 
(%) 
Top 5 genes 
(%) 
Top 10 genes 
(%) 
Missense and Nonsense 
Phen-Gen 82 89 91 97 98 98 
Genotype only 0 3 17 75 98 98 
Phenotype only 30 66 72 23 49 67 
Known 93 97 98 97 98 98 
Unknown 51 67 72 92 97 97 
 
Splice site 
Phen-Gen 80 85 85 87 87 87 
Genotype only 0 4 29 72 87 87 
Phenotype only 33 75 77 26 50 65 
Known 87 89 89 87 87 87 
Unknown 49 67 70 81 82 82 
 
Indels 
Phen-Gen 80 88 94 97 98 98 
Genotype only 0 1 2 64 98 98 
Phenotype only 31 72 74 24 56 72 
Known 94 98 98 97 98 98 
Unknown 25 47 75 96 97 97 
 
Combined (Missense, Nonsense, Splice site and Indels) 
Phen-Gen 81 88 91 96 97 97 
Genotype only 0 3 13 72 97 97 
Phenotype only 31 69 74 24 51 68 
Known 92 97 97 96 97 97 
Unknown 43 61 73 92 96 96 
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Online Methods 
Gene list 
We aimed to capture four popular gene lists (Consensus CDS, RefSeq, Ensembl and UCSC 
known). Incomplete transcripts were discarded in each database and only protein coding genes 
were considered. Alternatively spliced transcripts reported in the same data source were 
assigned to the same gene. The mapping from the first three databases to UCSC known gene list 
was downloaded and utilized to merge gene names across data sources. Additionally, two genes 
were merged if any of their isoforms exhibited greater than 95% identity in the exon sequence 
in the same orientation15 . Finally, an in-house mapping used for identifying alternate isoforms 
in the SIFT database was employed16 . The final gene list comprised of 26,803 protein coding 
genes with 11.4 gene or transcript identifiers reported per gene on average. This gene set was 
employed in all the experiments in the manuscript and any downloaded gene identifier was 
translated to this set. 
Variant prediction 
For the coding predictor, each called variant in the patient's genome (or exome) is evaluated if it 
lies within the coding regions in a reported transcript of the fore mentioned gene list, or if it 
falls within the splice site definition of the intron-exon boundary. The coding variants are further 
sub-categorized as start-loss, stop-gain, stop-loss, splice site, nonsynonymous, synonymous or 
indel. Each variant is assigned a probability of deleteriousness based on its highest estimated 
damaging impact. For the genomic predictor, all coding and noncoding variants are analyzed for 
their putative functional role.  
Nonsynonymous variants 
Nonsynonymous mutations are probably the best studied class of damaging mutations and a 
plethora of literature has been written and algorithms developed to evaluate their damaging 
impact. For our prediction we combined two commonly used algorithms SIFT16  and PolyPhen-
217 . The aim here is to estimate the probability of a non-synonymous mutation given its’ SIFT 
and PolyPhen-2 scores. We employed a positive and neutral dataset to estimate the empirical 
distribution of these scores both individually and in conjunction. The positive set comprised of 
disease causal nonsynonymous mutations from the Human Gene Mutation Database (HGMD)11. 
The neutral set contained nonsynonymous substitutions in the human reference genome with 
respect to the ancestral sequence as inferred from the human-chimp-gorilla exome alignment. 
Only the loci where both chimp and gorilla sequence aligned and agreed on the allele were 
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considered. The two distributions were combined using Bayes’ rule with prior probability of a 
nonsynonymous variant being damaging 0.6718. The two algorithms exhibit general agreement 
(Supplementary Fig. 2). Hence the two ends of the spectrum where the predictions disagree are 
quite sparse. The posterior probability in these bins was interpolated using the geometric mean 
of their nearest neighbors. PolyPhen-2 predictions tend to average out within each bin; adding 
SIFT scores helps differentiate and improve the probability estimates within each bin. The 
continuum of predicted probabilities can be thresholded to achieve 91% accuracy with less than 
2.1% false positives; which compares favorably with MutationTaster19 at 87% accuracy and 4% 
false positive rate using the same data. It needs to be emphasized though that the downstream 
analysis uses the probability estimates and not the binary predictions.  
Splice site variants 
Exon-intron boundary information was extracted for all the transcripts in the gene list from their 
respective databases. Mutations in the 8 base pair locus surrounding the donor site or the 3 
base pair locus surrounding the acceptor site (Supplementary Fig. 3) were considered splice 
disrupting. In particular the 2 base pair at the start and end of an intron tend to be more 
conserved and hence were treated separately20. To estimate the probability of deleteriousness 
of a mutation affecting splicing boundaries, we employed splice site disease causal mutations 
from HGMD as a positive set. The neutral set contained common mutations in dbSNP with 
minor allele frequency greater than 30% within the defined sites. The prior probability of a 
splice site mutation being damaging was estimated by the reduction in the number of common 
mutations at these sites in comparison to the whole genome. The rationale being that the 
mutation rate is assumed to be constant in a random subset of the genome; and this reduction 
in common mutations is attributed to prior mutations being pruned out by negative selection. 
The splice site definition fails to capture 8% of mutations reported in HGMD (with another 1% 
lying outside our gene list). A closer examination of these false negatives reveals that most of 
these sites are more than 10 bp away from our defined exon-intron boundaries. Some of these 
could reflect variability in transcript annotation; however others could potentially be 
introducing alternate splice sites which would not be represented in the prediction.  
Start-loss, Stop-gain and Stop-loss variants 
Start and stop codon altering mutations and nonsense mutations are highly deleterious and in 
most analysis are assumed to be damaging21 . We confirmed this hypothesis by computing the 
relative decrease in common mutations at these sites with respect to the complete genome. 
Once again, common mutations (MAF>30%) in dbSNP were used and these sites were defined 
using our gene set. Our analysis reveals that these mutations are highly likely to be damaging 
with probability 0.999.  
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Small insertions and deletions 
To estimate the potential damaging impact of a genic indel, we first classify them as either 
frameshift or non-frameshift. A different predictor is used for each class. In both cases, the 
respective disease causal indels from HGMD constitute the positive set. The neutral set 
comprises of common mutations from dbSNP (MAF>30%). The prior probability of a coding 
indel being damaging is estimated using 54 unrelated whole genome sequencing samples made 
publicly available by Complete Genomics Inc. The dataset revealed a strong exonic bias in indel 
calls, with 20% of indels located within 4% of the genome annotated as coding genes. To rectify 
for this bias, we compared the enrichment of rare indels (MAF<5%) and common indels 
(MAF>30%) within and outside the genes. The assumption being that both rare and common 
indels are impacted equally by the coding bias. Based on this computation, the prior probability 
of a genic indel being damaging was estimated to be 0.0787. This is a weak prior and the true 
value is likely to be higher. However because of higher false positive rate in calling indels (in 
comparison to SNPs) it would be prudent to err on the conservative side. Further the weak prior 
is rescued by strong observation in both indel categories.  All frameshift indels are assigned the 
probability of deleteriousness based on the empirical distribution of its positive and neutral set 
combined using Bayes’ rule. Non-frameshift indel predictions are further refined by 
incorporating the importance of the impacted locus (based on its tolerance to single nucleotide 
mutations).  
Genomic variants 
Next, we aimed to estimate the putative functional role of all genomic variants. To this end, 
conservation, putative regulatory interactions and proximity to genes were used to annotate the 
variants (Supplementary Fig. 4). Both GERP++22 and PhyloP23 (threshold 1.445) were used to 
define evolutionary conserved sites. ENCODE computational predictions for transcription factor 
binding sites and experimental annotations for DNASE hypersensitive sites were included. 
Proximity to gene annotations (including coding sequence, UTRs and 70 bp at the start and end 
of each intron) was incorporated. 
A key statistical challenge in estimating the functional role of noncoding mutations is the dearth 
of disease causal regulatory mutations in public datasets. Further, most studies focus on coding 
variants and hence dbSNP has accumulated a higher number of these variants over time. To 
correct for both these shortcomings, we employed two positive and two neutral datasets. 
Disease causal regulatory mutations in HGMD and reported GWAS hits (downloaded from NCBI) 
constituted the positive sets. The neutral sets contained common SNPs in dbSNP and common 
SNPs in publicly available unrelated sample data from Complete Genomics Inc (MAF > 0.30) 
respectively. Ten thousand permutations were performed and each positive and neutral dataset 
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was randomly selected with equal probability. Each selected dataset was subsampled, in each 
permutation, to estimate confidence intervals (Supplementary Fig. 5). The positive and neutral 
empirical distributions thus estimated were combined within Bayes’ rule. The prior probability 
of a random mutation in our annotated regions being damaging was estimated to be 0.0688. In 
addition to the fore mentioned annotations, we also considered further annotations including 
GUMBY24, noncoding RNA from GENCODE25, microRNA26 and GC content27. The technical 
difficulty in embracing more annotations stems from the small size of the positive sets. Adding 
more annotations increases the number of bins exponentially. This dilutes the signal within each 
bin, making it more susceptible to stochastic noise. GUMBY is stringent in its conservation 
threshold and thus quite accurate but not all-encompassing to all functional regions. 
Furthermore, 99.65% of GUMBY conserved sites overlapped with GERP++. MicroRNA predicted 
loci28 and GENCODE annotations29, despite their well established epigenetic role were not well 
represented in our positive sets. GC content was suggestive of the regulatory role when only 
HGMD was used as positive set; the predictive power disappeared when both positive sets were 
employed. This could potentially reflect the enrichment of de novo mutations in the HGMD 
dataset, as mutation rate across the genome tends to correlate with GC content27. These 
predictors can be further interrogated and perhaps rescued with increasing size of regulatory 
variant datasets. 
Pooling 
The estimated loss of function at the genic level is predicted by pooling damaging variants 
within each gene considering the most damaging predicted variants for maternally and 
paternally inherited chromosomes. If the haplotype phase information is not available, the first 
and second highest variants are considered under the assumption that they lie on opposite 
chromosomes.  Noncoding mutations are assigned to the nearest gene within 50 kb. This 
criterion is similar to conservative settings in GREAT30 and assumes potential cis regulatory 
impact of these variants on the respective genes. The inheritance pattern of the variants is 
compared against the disease inheritance pattern. For small pedigrees (such as trios or 
quartets) only variants consistent with this pattern are evaluated. For larger pedigrees, the 
flexibility to allow for nominal inconsistencies is permissible. This leeway is to account for 
potentially undiagnosed patients, incomplete penetrance, low coverage, and possible error in 
variant calls. Common variants are omitted from this pooling. For the prediction, any variant 
with reported minor allele frequency above 1% in either 1000 genomes31, National Heart, Lung, 
and Blood Institute Exome Sequencing Project (NHLBI ESP) or dbSNP32 version 135 is deemed 
common and excluded from consideration as the etiological variant. The analysis allows for the 
user to discard or incorporate variants inconsistent with the pedigree. Unless de novo mutation 
is the likely cause of the condition, the former is recommended. 
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Healthy individuals have been reported to harbor up to 100 damaging mutations33 . The 
distribution of these so-called deleterious variants is not uniform across all genes and certain 
genes (such as olfactory genes) are more likely to carry these loss-of-function variants. To 
account and rectify for these incidental red herrings, we compute a null distribution of our 
predictor for each gene using the samples from 1000 Genomes. These individuals have not been 
reported to suffer from any disorders and represent a generic snapshot of human genetic 
variability across the globe. The pooled probability distribution of each gene is estimated under 
both the dominant and recessive inheritance pattern (Supplementary Fig. 6). For a patient, only 
genes harboring variants which exceed the ninety ninth percentile of the corresponding null 
distribution are considered for downstream analysis. For example, more than 1% of 1000 
Genomes samples carry rare variants in CYP2C19 on both chromosomes with estimated 
damaging probability 0.88 or higher. Hence for a recessive disorder patient, CYP2C19 will only 
be considered as a candidate gene if there are two variants within the gene that both have a 
damaging probability higher than 0.88. A key advantage of our approach, in the context of the 
method, is that we establish a continuum of predicted loss of functionality of each gene within 
healthy individuals.   
Phenotypic prediction 
The patient’s disease symptoms are mapped to Human Phenotype Ontology database using an 
in-house replica of Phenomizer10. The aim here is to match the patient’s symptomatology to the 
list of known disorders and estimate the significance of each disease match. The Benjamini-
Hochberg multiple testing corrected p-values are translated to probabilities assuming disease 
set has a uniform prior. 
             
 
                
                        
 
 
                
                        
 
                  
                
                         
 
            
 
              
 
                        
 
 
Each disease probability is assigned to all genes implicated in literature for that disorder. If no 
genes are currently known, the probability is distributed uniformly across all genes. Certain 
genes are known to impact multiple disorders. Pleiotropy is accounted for by combining all the 
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assigned probabilities for a gene across the spectrum of disorders it has been reportedly 
involved in. 
                               
              
                                             
          
  
  
Thus far we have estimated the role of each gene leveraging on direct knowledge of their 
involvement in diseases with similar symptoms. Next we incorporate ‘guilt by association’ based 
on evidence of their interaction with a known perpetrator. To gather this circumstantial 
evidence, a random walk with restart is conducted on gene-gene interaction network. Each 
gene is selected as a starting point of the walk with probability Pgene. Restart probability of 90% is 
used for the walk. This translates to 90% of the phenotypically matched probability aka ‘guilt’ 
retained by the initial gene and 10% of it permeated across its known associates; with stronger 
evidence of interaction leading to a higher probabilities.   
Gene-gene interaction network construction 
In the context of the method, the gene-gene interactions are not just limited to physical 
interaction of genes. Rather they reflect the ability of two genes to impact the same underlying 
biology and thus lead to the same (or similar) disorders and symptoms. This information is 
agglomerated across different sources including known involvement in the same pathway or 
ontology domains, data-mined reports of co-occurrence across publications, and/or correlated 
co-expression among tissue types. The gene-gene interaction network is constructed by 
combining these sources in a framework inspired by ref. 34. A key difference is that the original 
study made binary predictions, thus representing an un-weighted graph; whereas we construct 
a randomized graph with edge weights proportional to confidence in interaction. The network 
construction is as follows. All pairs of genes reportedly involved in the same pathway 
(REACTOME35, KEGG36, NCI-Nature37) are considered true interactions. This confidence stems 
from the manual curation process of these sources by domain experts. To improve recall of the 
network, we supplement the pathway information with additional data sources. The pathway 
based interaction are used to evaluate the predictive power of data mining approaches 
(BioGRID38 , STRING39), Gene Ontology domains annotations40  (cellular component, molecular 
function, and biological process) and gene co-expression (COXPRESdb41 ). These predictions are 
combined within a unifying framework in a manner similar to ref.  34 with prior probability of 
two random genes interacting estimated from pathway databases. A high confidence (co-
involvement probability >=0.1) gene-gene interaction network was thus defined. In total, the 
network comprised of 920,898 interactions.  
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To test the efficacy of this network in representing genetic heterogeneity, gene pairs implicated 
for the same disorder were extracted from HGMD and OMIM (10,852 and 5,083 respectively). 
31% and 39% of these pairs are represented by a direct edge in the network (P<<10-16 based on 
distribution of random gene pairs) indicating that the probability of their involvement in similar 
diseases is well represented in the network; and that the network is significantly enriched in 
true interactions; which bodes well in its efficacy to elucidate novel gene involvements in known 
disorders.  
Disease causal genes tend to play a more central role in interactome. This is reflected in the 
gene-gene interaction network where HGMD and OMIM implicated genes tend to have a higher 
number of edges (P ≤10-166 and P ≤1.8×10-192 respectively). 
 
Combined 
Assuming phenotypic and genotypic probability estimates are independent observations of the 
same underlying probability of involvement of a gene we combine the two predictions for each 
gene within a Bayesian framework.  
                                      
           
                               
                                                                        
                                                                   
  
  
Computational efficiency 
Exome sequencing routinely yields 20,000 variants per sample; the number increases to 4 
million for whole genome sequencing. We employ a simultaneous linear scan of the variant and 
annotation files. To speed up the process ‘regions of interest’ were defined using interval 
forests; with one tree per chromosome. Overlapping intervals were merged to define a sieve 
which represents 19% of the genome. This allows the implementation to quickly sift out the 
variants of interest discarding the rest. To expedite the actual run-time execution, whenever 
possible, the burden of computation was moved to pre-processing and information stored in a 
binary format for faster reading, e.g. for noncoding variants the database overlap information is 
encoded in 1 byte per interval.  
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The source code, preprocessed databases and executables are provided as single downloadable 
package. This includes an in-house implementation of Phenomizer with limited functionality 
necessary for Phen-Gen. The source code is released under the GNU General Public License, so 
a computationally savvy user can make changes to incorporate further metrics of 
deleteriousness and improve on the model. We plan to periodically update the online and 
downloadable versions of Phen-Gen with each major release of the source databases. The 
software is also available as an online server for ease of use.  
 
Simulating in silico patients 
To evaluate Phen-Gen we generated in silico patients. For a given disorder, a patient’s genetic 
data was created by adding a known disease causal mutation from HGMD into a healthy 
individual with zygosity consistent with the reported disease inheritance pattern. These 
genomes on average harbor four million genomic variants, of which twenty four thousand are 
coding42. The patient’s phenotypic data was generated based on reported disease symptoms. 
Phen-Gen allows pedigree data, which considerably narrows down the search pool but in the 
simulations we aimed for the extreme case where only the lone patient information is available. 
In the first set of simulations, 765 diseases for which at least one causal variant was reported in 
HGMD and the disease symptoms were defined in OMIM4 were extracted. These symptoms 
were used to define the patient’s condition. Each causal variant was systematically spiked in 
each of the 1092 individuals from 1000 Genomes dataset in turn and the remaining individuals 
were used to define the null distribution (Tables 1 and Supplementary Tables 1 and 6).  
To evaluate Phen-Gen’s performance in identifying the disease causal gene with a compound 
heterozygous disease inheritance pattern a second set of simulations was conducted. In these, 
the general framework remained the same as before. But this time instead of a single variant, 
two variants were added to the patient genome in a heterozygous state on opposite 
chromosomes. For these simulations only recessive inheritance pattern disorders with at least 
two variants reported in (or near) the same gene were used with a simulated patient generated 
for every pair of reported variants (Supplementary Table 4). In the case where one or both of 
the members of a spiked variant pair was noncoding, the genomic variant predictor was used 
(Supplementary Fig. 8). 
To evaluate Phen-Gen’s robustness to phenotypic heterogeneity, 44 disorders for which the 
symptom list and their frequency of occurrence has been compiled11 were used. For each 
disorder, five medical histories were constructed by randomly sampling each symptom based on 
its frequency. The simulations were conducted in a similar manner as before, with the added 
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caveat that every individual patient genome was evaluated five times, once with each medical 
history (Supplementary Table 5).   
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VAAST, PHEVOR and eXtasy simulations 
The performance of Phen-Gen was compared against VAAST1, PHEVOR2, and eXtasy3. PHEVOR 
is a phenotype-based add-on tool which relies on genomic predictions from methods like 
VAAST. Both VAAST and eXtasy predict only on the damaging impact of amino acid changing 
SNVs and do not score indels, splice or noncoding variants. Hence for this comparison only 
nonsynonymous mutations in Human Gene Mutation Database (HGMD) were used. VAAST uses 
a unique file format (Genome Variant Format, or GVF) and their analysis package comes with 
conversion software to convert from VCFs to this format. Unfortunately, we faced compatibility 
issues with VCFs extracted for majority of the samples from African American population 
(ASW), within the 1000 Genomes data. To keep things simple, all ASW samples were removed 
from these. For computational efficiency, a random set of 1000 individuals were set aside as 
controls and 26 individuals were used to generate the simulated patients. For each causal 
variant, one individual was randomly selected and eXtasy, VAAST and Phen-Gen were run 
independently. The comparison was conducted using HGMD reported disease causal variants 
for which the disease symptoms are defined in OMIM. 
For VAAST the 1000 individuals served as controls to estimate the composite likelihood under 
the healthy model to be compared against the disease model. Phen-Gen and eXtasy provide a 
continuum of rankings whereas VAAST (on average) identifies 14 genes at the top of the list. For 
a fair comparison, the true causal gene for VAAST ranking was assigned best, average, and 
worst rank among similarly ranked genes. For example, if VAAST assigns the true gene along 
with 4 other genes the same top rank. The causal gene will be ranked as 1, 3 and 5 for best, 
average and worst respectively. This is reflected in the three components of the bar in VAAST 
results (Fig. 1). VAAST was able correctly narrow down the true causal gene to within 14 genes 
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(on average) in 62% of dominant and 78% of recessive cases. In comparison, Phen-Gen was able 
to identify the correct etiological gene in 82% cases for dominant and in 97% cases for recessive 
OMIM reported disorders. 
PHEVOR was recently published by the authors of VAAST. It combines information from 
multiple disease and functional ontology databases to re-prioritize genomic predictions in light 
of patient-specific symptoms. PHEVOR is only available as an online tool; making a 
comprehensive simulation comparison not possible. In its publication, PHEVOR was evaluated 
in 100 simulations. We chose the same number for our comparison. 50 dominant and 50 
recessive cases were randomly chosen from the VAAST simulations. As a sanity check, VAAST 
predictions of this subset were compared against VAAST results for all simulations to ensure 
that the subsample reflects the general trend. PHEVOR web server only allows up to 5 disease 
symptoms. If the phenotype description exceeds this number, 5 symptoms were randomly 
chosen. The combination of VAAST and PHEVOR was able to assign the causal gene top rank in 
66% of dominant and 68% of recessive simulations. In comparison for the same cases, Phen-
Gen was able to correctly identify the causal gene in 90% of dominant and 88% of recessive 
simulations (Fig. 1). 
The better performance of Phen-Gen can be attributed to methodological differences as well as 
difference in data sources integrated in the prediction. PHEVOR’s 'ontology propagation’ does 
not take in account the information content of its various data sources. Phen-Gen estimates 
this in the gene interaction network construction by relying on pathway databases. Pathway 
databases are often the best curated gene functional information available4. PHEVOR currently 
does not use this resource, although its authors concede integrating pathway information to be 
an active area of PHEVOR's development.  
eXtasy relies on locus and gene specific information and does not use a control population. 
Hence the control set was not used in its prediction. Under default settings it evaluates all 
variants both common and rare. In its manuscript it was evaluated with rare variants (MAF<1%) 
as well. eXtasy’s performance is thus evaluated under both scenarios. In the first, all variants in 
the individual exome were provided as an input. In the second, only rare variants were used 
and variants with MAF>1% in 1000 Genomes, dbSNP or National Heart, Lung, and Blood 
Institute’s Exome Sequencing Project (ESP) were discarded. eXtasy is able to narrow down the 
causal variant within top 10 variants in 69% of the cases for dominant and 76% of the cases for 
recessive disorders. In comparison Phen-Gen is able to narrow down the causal variant within 
10 variants in 91% of the cases for dominant and 98% of the cases for recessive disorders. The 
relative advantage of Phen-Gen can potentially stem from multiple factors. eXtasy does not 
incorporate the disease inheritance pattern in its prediction. It also ranks variants based on 
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individual phenotypes. Although the information is combined in rank aggregation, the interplay 
of different combination of phenotypes may not be well represented.  
For the comparison Phen-Gen used the identical control set of 1000 individuals from VAAST to 
define the null distribution of genes. Phen-Gen outperforms eXtasy, VAAST and VAAST+PHEVOR 
by 19-58% (Fig. 1). eXtasy currently only allows a subset of disease symptoms defined in Human 
Phenotype Ontology. To investigate Phen-Gen’s relative advantage due to a more 
comprehensive symptom list, Phen-Gen simulations were repeated restricting it to the 
symptoms accepted by eXtasy; Phen-Gen’s ability to identify the true disease causal gene 
dropped by 1% in these simulations (results not shown). 
For further comparison with VAAST, 44 phenotypic heterogeneous dataset was employed. The 
results show the relative performance and highlights Phen-Gen’s advantage even when disease 
symptoms are not completely specific (Supplementary Fig. 8).  
 
Performance using real dataset 
Phen-Gen was evaluated using a recently published real dataset comprising of one hundred 
parents-child trio families with the children exhibiting intellectual disability symptoms5. This 
data contains variant calls for each family, as well as a rich resource of medical history detailing 
each patient’s unique symptoms. The information was initially electronically parsed, and then 
manually evaluated by two of the authors independently to absolve the translation to Human 
Phenotype Ontology terms from any ambiguities. Further advice from a clinician was sought to 
remove any errors of interpretation. 
On the genotypic side, a key challenge in handling the real dataset was the noise level in the 
variant calls. In the original study itself, the focus was on de novo mutations and the provided 
‘high quality calls’ cast an initial wide net to encompass large number of candidate mutations. 
In the original publication, these calls were pruned by further bioinformatic processing and 
finally bench validation. Replicating this effort required access to the patient samples 
themselves, which was not possible. The validation rate of de novo mutations reported even 
after further bioinformatic processing was 11.4%3. To sidestep validation issues due to noise 
level in the data and focus on the downstream analysis that Phen-Gen aims to provide, we 
initially focused on eighteen families with variants implicated in recessive or X-mode 
inheritance. Seven families were further removed from consideration as the variants reported 
in the publication were not observed in the correct inheritance pattern in the provided data 
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and had likely been corrected in the bench validation3. Hence eleven families were used in this 
current study. 
The performance of Phen-Gen is evaluated for variants reported in the original publication 
(Supplementary Table 7). Phen-Gen allows for variants with MAF below 1% in public databases. 
The first column of Phen-Gen results depicts the performance in this scenario. The original 
study however discarded all known variants (already existing in dbSNP, or observed in their in-
house database). After adopting the same filtering criteria as the original study, 16/21 genes 
agreed with the original study, and only five are potentially false positives. Of these five 
variants, two were homozygous in the patient and observed in heterozygous state in two 
different families and the remaining three are only observed in the respective family. Of the 
three novel variants two are indels which were not evaluated in the original study. These five 
variants cannot be ruled out as disease causal candidates based purely on the bioinformatics 
analysis of the variant calls and further bench validation and functional analysis would be 
needed to implicate or exonerate them. 
Intellectual disability is a genetically diverse disorder and it has been estimated that more than 
a thousand different genes may be playing a role6. Thus despite the rich and detailed patient 
history, it is challenging to list it down to a few genes based purely on symptomatic knowledge. 
We analyzed the symptoms of 58 patients with reported recessively inherited deleterious 
mutations, de novo mutations, or X-linked mutations in males (Supplementary Tables 3 and 9 in 
the original publication5). The analysis relied only on just the phenotypic information to rank 
the genes for each patient. To quantify the performance of our approach, we computed the 
sum of the ranks of all reported genes in the respective patient’s phenotypic match. The aim of 
this analysis is to highlight that the genes reported in the original study based on genetic 
evidence tend to have a significantly lower rank in our lists than observed just by chance. Each 
individual patient’s rank should have a uniform distribution under the null hypothesis and 
hence their sum - an Irwin-Hall distribution- is approximated by a Normal distribution. The 
results indicate that the rank sum of reported genes is significantly lower than expected by 
chance (P ≤ 0.0036).  
The authors split the gene set into known, unknown and candidate genes.  The ‘known genes’ 
had been implicated for intellectual disability in prior literature. ‘Candidate genes’ had not been 
directly reported for intellectual disability, but are linked to brain and embryonic development 
and there is further evidence of their involvement. The remaining genes are deemed 
‘unknown’. Even when we focused on individual gene subclasses, the rank sums in all three 
categories were significantly lower: known genes (P ≤ 2.44×10-8), candidate genes (P ≤ 0.0051), 
and unknown genes (P ≤ 0.0192). In the original study, only known genes carrying deleterious 
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variants were considered confirmed as diagnosed; or if the same candidate gene harboring 
damaging mutations was observed in two different patients with similar symptoms. Known 
genes implicated in these patients are expected to be ranked lower. Our results indicate that 
although the unknown genes set could harbor a lot of incidental genes, they are likely to 
contain some true positives as well; and the diagnostic yield of this dataset can potentially be 
improved by further corroboration.  
Comparison with PHIVE 
PHIVE7  was evaluated in a simulation framework similar to the one presented in this paper. The 
authors used a somewhat different HGMD version (869 diseases versus 765 for Phen-Gen) and 
this could potentially contribute to the difference in results. Since PHIVE is only available as an 
online server and not a downloadable package, it is not possible to do a comprehensive 
evaluation using the same dataset. The authors report 66% power to identify the causal gene in 
dominant and 83% in recessive disorders. Comparison of these reported results reveals Phen-
Gen has 13-16% higher efficacy in identifying the true causal mutation in both dominant and 
recessive disorders (Table 1). This advantage may be attributed to different factors including 
the underlying prediction framework and better representation of the disease symptoms in 
human databases.  
PHIVE uses phenotypes from mouse gene knockout experiments to establish phenotype to 
gene links. Using the mouse model to represent human phenotypes has a few limitations. 
Mouse knockout experiments have only been conducted for approximately a third of the 
human genes. There has been increasing focus in the recent past to generate a more 
comprehensive resource8, and this would improve PHIVE predictions over time. In comparison 
human disease-gene association span only about 10% of the genes. Both these numbers 
support the usage of gene (or protein) interaction networks to extrapolate predictions to the 
remaining set of genes. PHIVE assigns a uniform phenotypic score to the 2/3rd gene set and the 
authors concede that integrating protein interaction information is a potential future direction 
to improve results. A second issue which would be more difficult to address is that human and 
mice do not share disease morphology for all disorders9. In particular it would not be 
representative of any primate specific, or even more constrained human-specific, traits. Ward 
and Kellis recently showed that a large number of human regulatory regions do not show 
evolutionary conservation in primate evolution10, so the mouse model may not recapitulate 
recently acquired regulatory evolving traits. Despite these limitations, animal models provide 
an invaluable resource and integrating this information along with human disease matches is 
one avenue to improve Phen-Gen’s predictions.  
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On the genotypic side, PHIVE assigns arbitrary pathogenicity scores for the different classes of 
coding mutations (all except missense). These scores were chosen to give optimal predictions 
within their simulation framework. Their performance declined by almost half in simulations 
spiking the causal variant in in-house exomes (Fig. 4a of the publication7). The authors 
attributed this decline to their reliance on allele frequency information which would be 
unavailable for novel variants observed in the in-house data. This issue will be faced during the 
analysis of any new dataset. Another factor potentially playing a role is that the 1000 Genomes 
data is highly curated and fine-tuning the predictions based on this dataset may have led to 
overfitting. For example, the indel calls in the public data have been improved in extensive 
bench validations11, whereas in a practical scenario these calls tend to be more error prone. 
Comparison with FunSeq 
FunSeq12 evaluates the regulatory role of a noncoding mutation using a combination of 
functionality categories similar to Phen-Gen. It identifies the top 0.4% of the genome as 
‘sensitive’ to regulatory disrupting mutations. The selective constraint in each combination of 
annotations is estimated using enrichment of rare variants. FunSeq annotations are highly 
predictive of functionality but may not necessarily be all-encompassing. The method follows 
multiple screening steps to reduce the number of candidate mutations. Analysis of HGMD 
reported disease causal regulatory variants reveals that their initial filter (representing coding 
and sensitive regions) only captures 18% of these damaging variants and would annotate the 
rest as benign. Phen-Gen on the other hand assigns a continuum of probabilities to 80% of the 
variants. These variants are assigned a lower probability based on genotypic information 
(Supplementary Fig. 7). These variants would likely be poorly predicted by any genotype only 
approach and would require phenotypic support for improved predictions. Simulation results 
support this hypothesis; Phen-Gen is able to specify the true causal variant regulatory mutation 
in 49% of the cases with phenotype information (Supplementary Table 6). This predictive power 
stems from phenotypic corroboration with a 30 percentage points advantage in predicting the 
true causal gene compared to a purely genotype only approach; thus highlighting Phen-Gen’s 
advantage of integrating this viable resource. In 69% of the cases, the disease gene appeared in 
Phen-Gen’s top 10 list of candidate. 
 
Prior probability for genomic predictor 
It is estimated that about 10-15% of the genome is functionally active13. Assuming the average 
of these estimates and that all functional loci reside within our regions of interest span 19% of 
7 
 
the genome, we can compute the probability of a random annotated locus being functional to 
be 12.5/19 = 0.66. Next to compute the probability of a mutation at a functional region being 
deleterious, we used the PhyloP conserved bases as surrogates of the functional genome and 
computed the reduction in common mutations in dbSNPs (MAF>30%) at these sites in 
comparison to the rest of the genome. These numbers were combined to yield the probability 
of an annotated variant being damaging 0.0688 which is used as prior in the genomic predictor. 
Incorporating pedigree information 
For a dominant disease inheritance pattern genes harboring one or more damaging mutations 
are evaluated. Predicted damaging variants with one or more copies of the alternate allele in all 
cases and no copies of alternate allele in controls are considered. Only genes with a predicted 
probability higher (or equal) in cases than controls are incorporated in the downstream 
analysis. 
For a recessive or compound heterozygous disease inheritance pattern, genes harboring two or 
more damaging mutations are evaluated. Predicted damaging variants with one or more copies 
of the alternate allele in all cases and one or zero copies of the alternate allele in controls are 
considered. Only genes with a predicted probability higher in cases than controls are 
incorporated in the downstream analysis. This allows for compound heterozygosity while 
reducing the false positives. If both parents are included in the analysis, there is a further filter 
to require at least one variant from each parent.  
Phen-Gen allows the user to restrict the analysis to variants consistent with the pedigree 
structure of the family. This is the recommended settings as pedigree inconsistent variants 
harboring potential de novo mutations also tend to be enriched in sequencing errors. The 
software allows the user with leniency in this criterion by allowing pedigree-inconsistent 
variants if de novo mutations are the likely cause of the condition. In practice for real datasets 
however it is highly recommended to use a pedigree based variant caller (such as GATK 2 
PhaseByTransmission walker) to prune out false de novo calls. 
Evaluating null distribution of genes 
To evaluate Phen-Gen’s null distribution of genes we compared our predicted deleterious 
variant harboring genes with loss of function genes reported in ref.  11 and Residual Variation 
Intolerance Score (RVIS) reported in ref 14. Ref. 11 used a subset of 1000 Genomes individuals 
for their analysis and the predicted damaging variants were subsequently curated after further 
bench validations. Ref. 14 used NHLBI ESP allele frequencies and corrected for gene size as 
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larger genes are more likely to harbor incidental so-called damaging variants due to size. A 
cutoff of ninety fifth percentile was employed to their set of damaging variant harboring genes. 
Phen-Gen employs a one percentile cutoff for the null distribution. Despite methodological and 
dataset differences, genes which exceed this cutoff showed high enrichment in the respective 
datasets (P ≤ 8×10-3 for McArthur et al and 10-2 for Petrovski et al using Fisher’s exact test).  
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 Supplementary Table 1 
 Additional statistics for results reported in Table 1 
Performance in simulated patients with OMIM-listed disease symptoms and HGMD reported 
variants for coding predictor. The table is an extension of Table 1 with performance for 
genotype and phenotype-only predictors added for both known and unknown diseases in each 
category (see highlighted rows). The number of variants in each category is also included at the 
top of each table. The performance of both genotypic and phenotypic predictors in each 
category is presented. The percentage of known (gene disease association in the local 
Phenomizer database) and unknown variants in each category is also reported.  
  Dominant   Recessive 
  
Top 
gene 
(%) 
Top 5 
genes 
(%) 
Top 10 
genes 
(%) 
  
Top gene 
(%) 
Top 5 
genes 
(%) 
Top 10 
genes 
(%) 
Missense & Nonsense 9,194 variants, 1092 individuals   11,028 variants, 1092 individuals 
Phen-Gen 
All 
82 89 91  
All 
97 98 98 
Genotype 
only 
0 3 17 
 
75 98 98 
Phenotype 
only 
30 66 72 
 
23 49 67 
Phen-Gen 
Known 
(74%) 
93 97 98  
Known 
(91%) 
97 98 98 
Genotype 
only 
0 3 19 
 
75 98 98 
Phenotype 
only 
37 80 84 
 
25 51 68 
Phen-Gen 
Unknown 
(26%) 
51 67 72  
Unknown 
(9%) 
92 97 97 
Genotype 
only 
0 3 13 
 
72 96 97 
Phenotype 
only 
12 26 40 
 
13 29 54 
          
Splice site 1,581 variants, 1092 individuals   1,899 variants, 1092 individuals 
Phen-Gen 
All 
80 85 85  
All 
87 87 87 
Genotype 
only 
0 4 29 
 
72 87 87 
Phenotype 
only 
33 75 77  26 50 65 
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  Dominant   Recessive 
  
Top 
gene 
(%) 
Top 5 
genes 
(%) 
Top 10 
genes 
(%) 
  
Top gene 
(%) 
Top 5 
genes 
(%) 
Top 10 
genes 
(%) 
Phen-Gen 
Known 
(81%) 
87 89 89  
Known 
(94%) 
87 87 87 
Genotype 
only 
0 4 30  72 87 87 
Phenotype 
only 
39 87 89  28 52 67 
Phen-Gen 
Unknown 
(19%) 
49 67 70  
Unknown 
(6%) 
81 82 82 
Genotype 
only 
0 4 25  72 82 82 
Phenotype 
only 
5 20 26  3 16 43 
          
Indel 5,972 variants, 1092 individuals   4,220 variants, 1092 individuals 
Phen-Gen 
All 
80 88 94  
All 
97 98 98 
Genotype 
only 
0 1 2  64 98 98 
Phenotype 
only 
31 72 74  24 56 72 
Phen-Gen 
Known 
(80%) 
94 98 98  
Known 
(91%) 
97 98 98 
Genotype 
only 
0 1 1  64 98 98 
Phenotype 
only 
38 87 89  26 59 73 
Phen-Gen 
Unknown 
(20%) 
43 61 73  
Unkown 
(9%) 
92 96 96 
Genotype 
only 
0 2 11  70 95 96 
Phenotype 
only 
8 21 32  11 27 56 
          
Combined 16747 variants, 1092 individuals   17147 variants, 1092 indviduals 
Phen-Gen 
All 
81 88 91  
All 
96 97 97 
Genotype 
only 
0 3 13  72 97 97 
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  Dominant   Recessive 
  
Top 
gene 
(%) 
Top 5 
genes 
(%) 
Top 10 
genes 
(%) 
  
Top gene 
(%) 
Top 5 
genes 
(%) 
Top 10 
genes 
(%) 
Phenotype 
only 
31 69 74  24 51 68 
Phen-Gen 
Known 
(77%) 
92 97 97  
Known 
(91%) 
96 97 97 
Genotype 
only 
0 3 14  72 97 97 
Phenotype 
only 
38 83 86  26 53 69 
Phen-Gen 
Unknown 
(23%) 
43 61 73  
Unknown 
(9%) 
92 96 96 
Genotype 
only 
0 2 11  70 95 96 
Phenotype 
only 
8 21 32  11 27 56 
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Supplementary Table 2 
Performance in novel disease gene discovery 
 The simulations are conducted with OMIM-listed disease symptoms and HGMD reported 
variants. In each category, Phen-Gen is evaluated with the knowledge of the respective known 
disease gene association masked from the simulation. The results are highlighted. Across all 
masked and unknown simulations Phen-Gen assigns the causal variant top rank in 71% of cases. 
For a comparison, Phen-Gen’s performance in the known and unknown categories is also 
included from Supplementary Table 1. The results indicate a drop in performance for novel 
gene discovery in comparison to known associations, and highlight comparable performance to 
the true unknown cases. Since prior disease knowledge impacts only the phenotypic part of the 
prediction, Phen-Gen’s prediction performance based solely on the phenotype is also included.  
  Dominant  Recessive 
  
Top 
gene 
(%) 
Top 5 
genes 
(%) 
Top 10 
genes 
(%) 
 
Top gene 
(%) 
Top 5 
genes (%) 
Top 10 
genes 
(%) 
Missense & Nonsense    
Known 
Phen-Gen 93 97 98  97 98 98 
Phenotype 
only 
30 66 72 
 
25 51 68 
Masked 
Phen-Gen 58 78 84  90 97 98 
Phenotype 
only 
13 23 26 
 
12 17 18 
Unknown 
Phen-Gen 51 67 72  92 97 97 
Phenotype 
only 
12 26 40 
 
13 29 54 
         
Splice site    
Known 
Phen-Gen 87 89 89  87 87 87 
Phenotype 
only 
39 87 89  26 50 65 
Masked 
Phen-Gen 47 61 64  83 87 87 
Phenotype 
only 
5 18 20  14 22 23 
Unknown 
Phen-Gen 49 67 70  81 82 82 
Phenotype 
only 
5 20 26  3 16 43 
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  Dominant  Recessive 
  
Top 
gene 
(%) 
Top 5 
genes 
(%) 
Top 10 
genes 
(%) 
 
Top gene 
(%) 
Top 5 
genes (%) 
Top 10 
genes 
(%) 
Indel    
Known 
Phen-Gen 94 98 98  97 98 98 
Phenotype 
only 
38 87 89  26 59 73 
Masked 
Phen-Gen 55 69 74  88 97 97 
Phenotype 
only 
12 23 25  11 21 23 
Unknown 
Phen-Gen 25 47 75  96 97 97 
Phenotype 
only 
2 12 16  7 25 65 
         
Combined    
Known 
Phen-Gen 93 97 97  96 97 97 
Phenotype 
only 
34 76 80  25 53 69 
Masked 
Phen-Gen 56 73 78  89 96 97 
Phenotype 
only 
12 23 25  12 19 20 
Unknown 
Phen-Gen 43 61 73  92 96 96 
Phenotype 
only 
8 21 32  11 27 56 
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Supplementary Table 3  
Performance when only ESP is used as MAF filter 
Performance in simulated patients with OMIM-listed disease symptoms and HGMD reported 
variants using only ESP common variants (minor allele frequency >1%) for filtration. The results 
when all three databases (ESP, dbSNP, 1000 Genomes) are used to define common variants are 
copied from Table 1 to indicate a drop in performance. The data shows that using all three 
databases to define common variants, confers a 13-21% advantage.  
 
  Dominant Recessive 
 
MAF 
filtration 
database 
Top 
gene  
(%) 
Top 5 
genes  
(%) 
Top 10  
genes 
(%) 
Top 
gene  
(%) 
Top 5 
genes  
(%) 
Top 10  
genes 
(%) 
Missense +  
Nonsense 
ESP 69 81 84 76 92 94 
All 3 82 89 91 97 98 98 
Splice site 
ESP 69 80 82 73 86 86 
All 3 80 85 85 87 87 87 
Indels 
ESP 66 83 83 73 94 95 
All 3 80 88 94 97 98 98 
Combined 
ESP 68 82 84 75 92 94 
All 3 81 88 91 96 97 97 
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Supplementary Table 4  
Performance in diseases with compound heterozygous inheritance pattern 
Performance for compound heterozygous mutation pairs in coding and genomic regions is 
depicted. The table entries reflect the percentage of simulations in each category with the 
indicated result. The results are similar to the 96% observed for recessive simulations in Table 1 
for coding variants. 
  
Coding  Genomic 
Top gene  
(%)  
Top 5 genes  
(%)  
Top 10 genes  
(%)  
Top gene  
(%) 
Top 5 genes  
(%)  
Top 10 genes  
(%)  
Phen-Gen 97 98 98 30 59 62 
Genotype only 25 98 98 8 16 35 
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Supplementary Table 5 
Robustness to symptomatic heterogeneity 
Performance in 44 disorders with variable symptoms is depicted. There were no indels reported 
for recessive disorders and only one genomic variant. Hence simulations for these variants were 
omitted. The table entries reflect the percentage of simulations in each category with the 
indicated result. This is a 5-7% drop off in performance in comparison to known diseases in 
Table 1 (92% for dominant and 96% for recessive). These results highlight Phen-Gen’s 
robustness to symptomatic heterogeneity.  
  Dominant Recessive 
 
 
Top gene 
(%) 
Top 5 genes 
(%) 
Top 10 
genes (%) 
Top gene 
(%) 
Top 5 genes 
(%) 
Top 10 
genes (%) 
Phen-Gen 
Missense & 
Nonsense 
88 95 97 90 95 96 
Splice site 86 89 89 86 88 89 
Indels 87 91 94    
Combined 87 92 95 89 94 95 
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Supplementary Table 6  
Performance in simulated patients for regulatory predictor 
The performance in simulated patients with OMIM listed disease symptoms and HGMD 
regulatory disease causal variants is shown. Phen-Gen’s genomic predictor was used for these 
simulations. The table entries reflect the percentage of simulations in each category with the 
indicated result. 
  Dominant Recessive  
Combined  
(dominant + recessive) 
  
Top 
gene 
(%) 
Top 5 
genes 
(%) 
Top 10 
genes 
(%) 
Top 
gene 
(%) 
Top 5 
genes 
(%) 
Top 10 
genes 
 (%) 
Top 
gene  
(%) 
Top 5 
genes 
(%) 
Top 10 
genes  
(%) 
Regulatory 
Phen-Gen 58 64 65 40 61 72 49 62 69 
Genotype only 1 2 2 34 51 62 19 29 34 
Phenotype only 31 43 54 5 11 26 17 26 39 
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Supplementary Table 7  
Performance in real patients 
The table reflects performance of Phen-Gen for recessive and X-linked implicated variants in 
real familial data5 . The trio IDs correspond to the family identifiers in ref 2. Similarly the gene 
classification reflects prior knowledge of the gene’s involvement in intellectual disability as 
defined in the original publication. Phen-Gen employs a 1% MAF cutoff whereas the original 
publication removed all variants reported to dbSNP or observed in their in-house database. For 
the latter screen all variants common amongst the families was employed. The performance 
using both these cutoff is depicted.  
Trio ID Gene Classification 
Phen-Gen’s Rank 
Inclusive  
of dbSNP  
MAF<1% 
Filtration criteria 
from ref. 2 
4 FANCB Unknown 18 3 
4 PDHA1 Known 5 2 
4 GUCY2F Unknown 4 1 
16 ENOX2 Unknown 2 1 
18 ARHGEF9 Known 8 1 
25 GPM6B Unknown 7 1 
41 ARHGEF9 Known 1 1 
42 DDX26B Unknown 13 3 
72 PDZD11 Unknown 3 3 
93 TRPC5 Candidate 4 1 
12 SYCP2L Unknown 2 1 
12 VPS13B Known 14 4 
12 C8orf59 Unknown 4 2 
12 PRUNE2 Unknown 7 3 
24 PCNT Known 7 2 
70 IQGAP2 Unknown 6 1 
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Supplementary Figure 1 
Overall Workflow. 
Patient disease symptoms are matched against known disorders and the probability of a symptomatic match is assigned 
to genes implicated for the respective disorder. These probabilities are permeated to known gene associates using a 
random walk with restart on the interaction network. In parallel the patient’s sequencing data is analyzed and the 
damaging impact of each variant estimated and pooled within genes. These two predictions are combined to implicate the 
gene(s) involved. 
 Supplementary Figure 2 
Distribution of SIFT and PolyPhen-2 scores for damaging and benign nonsynonymous mutations. 
The distribution of SIFT and PolyPhen-2 scores for HGMD-reported damaging nonsynonymous mutations and neutral 
nonsynonymous fixed substitutions inferred from human-chimp alignment are shown. The plots indicate general 
agreement between the two methods. 
 Supplementary Figure 3 
Deleteriousness predictions around splice site. 
The figure depicts the probability of deleteriousness around donor and acceptor sites for splice site mutations. 
 Supplementary Figure 4 
Probability of deleteriousness using the genomic predictor 
The figure illustrates the predicted deleteriousness of different combination of five annotations: GERP++ (G), PhyloP (P), 
near-genic (N), transcription factor binding sites (T), and DNASE hypersensitive sites (D). The predictions are binned 
according to the number of annotations (shown on the x-axis). Each bin is further canonically sorted based on the fore 
mentioned order of annotations. 
 Supplementary Figure 5 
Confidence intervals for positive and benign mutation set combinations. 
The 90% confidence intervals of different combination of genomic annotations are shown. The order from Figure S5 is 
maintained. With the four sub-figures representing combinations of the two positive sets (HGMD and GWAS) and the two 
neutral sets (common variation in dbSNP and Complete Genomics MAF>0.30), respectively. 
 Supplementary Figure 6 
Histogram of null distribution of deleteriousness of genes. 
The top 1 percentile of damaging variants in each gene is shown. The histogram of this null distribution cutoff for all genes 
under dominant and recessive inheritance pattern for coding and genomic predictors is shown. Most genes do not harbor 
any putative damaging variants and hence the distributions are dominated by the left most bar; which has been truncated 
for better visual representation. 
 Supplementary Figure 7 
Performance of variant predictors 
The distribution of damaging probabilities assigned to different classes of HGMD variants is shown. The top three panels 
employ the coding predictor. A genomic predictor was used for the bottom panel and applied to noncoding regulatory 
variants. The histograms depict the distribution of the scored variants. The pie charts on the right explicate the distribution 
of omitted and predicted variants in each category. Common variants (light blue) were observed in 1000 Genomes, ESP, 
or dbSNP with MAF ≥ 0.01. Commonly mutated genes indicate that the variants failed to exceed the null distribution of the 
respective gene (turquoise). Missed indicates that the variant eluded our regions of interest (dark blue). 
 Supplementary Figure 8 
Prediction of heterozygous variants. 
The figure depicts how compound heterozygous variants are evaluated. When both damaging variants reside within the 
coding region, the coding predictor is used to estimate the damaging impact of these variants. In cases when one or both 
variants lay outside the exon boundaries, both variants are evaluated using the genomic predictor. 
 Supplementary Figure 9 
Phen-Gen and VAAST comparison for phenotypically heterogeneous disorders. 
The comparison of Phen-Gen and VAAST in simulations using 44 phenotypically heterogeneous disorders and 
nonsynonymous mutations in HGMD is shown. In both panels the ability of both methods to narrow down the true gene 
search within 1, 5 and 10 genes is depicted. For Phen-Gen, the bar is split into the predictive power based on genotypic 
prediction and the added advantage gained from disease symptoms. VAAST only uses the genomic data and assign 
multiple genes the same rank at the top of the order. For a fair comparison, the true gene was assigned the worst, 
average and best rank among similarly ranked peers. The three components of the bar reflect the performance across 
these scenarios. 
 
